News | Antiplatelet and Anticoagulation Therapies | May 18, 2018

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin

Understanding the real-world performance of systemic anticoagulation in atrial fibrillation

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral anticoagulants do not maintain adherence above 80 percent. This leads to increased risks for thromboembolic events. This was according to a new study presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

Anticoagulation (AC) mitigates risk of thromboembolic events (TE) in patients with non-valvular atrial fibrillation (AF or Afib). Warfarin for decades, and recently direct oral anticoagulants (DOACs — a newer term for novel oral anticoagulants, or NOAC) have been effective. Real-world data have pointed to inconsistent adherence to anticoagulation, but it is not clear if event risk is elevated during gaps or if events occur even during periods of adherence.

The cohort included 52,365 patients prescribed warfarin and 67,686 prescribed any of the four DOACs. Lower adherence occurred in 47% of patients using warfarin and 31% on DOACs. Compared to higher-adherence warfarin, thromboembolic events were 14% less likely for higher-adherence DOAC (P<0.001), 48% more likely for lower-adherence warfarin (P<0.001) and 69% more likely for lower-adherence DOAC (P<0.001).

This observational cohort study evaluated administrative claims for patients in the IBM Watson Health Market Scan databases receiving a prescription of warfarin or a DOAC for anticoagulation for nonvalvular atrial fibrillation (NVAF) from  2015 to 2016. Exclusions were CHA2 DS2-VASc 0-1, transient AF, other requirement for AC, thrombocytopenia and anemia. The remaining patients were stratified based on index prescription (warfarin or DOAC). Outcomes, through December 2016, were hospitalization for TE (ischemic stroke or systemic embolism), hemorrhagic stroke or major bleeding. Event rates are reported for warfarin and DOACs at higher adherence (dosage covering >80% of days) and lower adherence (covering 40-80% of days). A Cox proportional-hazards model will incorporate basic characteristics, comorbidities and a time-dependent covariate for anticoagulation based on prescription dosage to associate adherence to outcomes.

Researchers said they plan to update the abstract with 2017 data and use the time-dependent Cox model to determine if event risk is higher during medication usage or gaps in adherence. Patients with lower adherence may be candidates for device therapies that obviate the need for chronic AC.

The study was presented by Dhanunjaya R. Lakkireddy, M.D., FHRS, from Kansas City Heart Rhythm Institute in Overland Park, Kansas.

 

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

#HRS2018 #HRS18

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init